StockData

Royalty Pharma vs Sarepta Therapeutics

RPRX and SRPT side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How RPRX and SRPT compare

Royalty Pharma is the larger company, worth 23 times as much as Sarepta Therapeutics ($39.9B against $1.7B).

Royalty Pharma grew revenue faster over the last twelve months (11.4% versus −18.9% for Sarepta Therapeutics).

Royalty Pharma keeps more of each dollar of sales as profit, with a net margin of 25.7% compared with −5.9% at Sarepta Therapeutics.

Royalty Pharma pays a dividend yielding 1.7%; Sarepta Therapeutics does not pay one.

Sarepta Therapeutics scores higher on the StockData Score (11 against 8 for Royalty Pharma), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricRPRXSRPT
Size and price
Market cap$39.9B$1.7B
Share price$69.31$16.07
Change, 1 year75.1%−10.7%
Change, 5 years66.8%−79.9%
Beta (5Y)0.410.99
Employees100835
StockData Score
Total score811 (better)
Valuation score03 (better)
Growth score2 (better)1
Performance score13 (better)
Health score34 (better)
Dividend score2 (better)0
Valuation
P/E48.8×–
P/S15.2×0.9× (better)
P/B–1.1×
EV/EBITDA34.0×–
P/FCF–9.6×
PEG0.30–
FCF yield–10.4%
Fair value$43.25$104.78
Margin of safety−60.3%84.7% (better)
Growth
Revenue growth (TTM)11.4% (better)−18.9%
Revenue growth, 5Y average2.3%32.4% (better)
Net income growth (TTM)−12.0%–
EPS growth (TTM)−12.9%–
EPS growth, 5Y average6.2%–
Profitability
Operating margin57.1% (better)−2.5%
Net margin25.7% (better)−5.9%
FCF margin–9.0%
Return on equity–−7.6%
Return on invested capital–−5.3%
Financial health
Debt / equity–0.10
Net debt / EBITDA5.38–
Interest coverage4.0×–
Current ratio1.293.46 (better)
Altman Z-score3.06 (better)−0.22
Piotroski F-score5 (better)3
Dividends and buybacks
Dividend yield1.7%–
Buyback yield0.66%–
Shareholder yield2.3% (better)0.00%
Ownership
Held by institutions63.8%102%
Held by insiders22.6%5.9%
Insider net buying, 12 months−$82.2M−$417K (better)
Superinvestors holding2–
Short interest, % of float2.9%19.4%

Go deeper

Other comparisons

For information only, not investment advice. Check the source filings before relying on any figure.